Skip to main content

IMCD to acquire the life science business of YCAM in South Korea and expand its footprint in the beauty and personal care markets

Written by Customer Service on . Posted in Mergers And Acquisitions.

IMCD to acquire the life science business of YCAM in South Korea

From left to right: JaeJoong Kim, Sales Director of YCAM, Fenna van Zanten, Director M&A and member of IMCD Group Executive Committee, Munkyum Kim, CEO of YCAM, Dongjoon Lee, Managing Director of IMCD Korea, Peter Shin, Finance Director of IMCD Korea
From left to right: JaeJoong Kim, Sales Director of YCAM, Fenna van Zanten, Director M&A and member of IMCD Group Executive Committee, Munkyum Kim, CEO of YCAM, Dongjoon Lee, Managing Director of IMCD Korea, Peter Shin, Finance Director of IMCD Korea

ROTTERDAM, The Netherlands (18 December 2024) – IMCD N.V. (“IMCD” or “Company”), a global leading distribution and formulation partner of speciality chemicals and ingredients, has signed an agreement to acquire the personal care and pharmaceutical business of YCAM Corporation, a distributor based in South Korea (“YCAM”).

Founded in 2010, YCAM specialises in distributing speciality ingredients for the cosmetics, personal care, and pharmaceutical markets. YCAM represents leading global suppliers and focuses on providing customers with formulatory advice and specialty ingredients through its technical team and laboratory support, helping them to stay abreast of market trends. YCAM is located in Anyang, South Korea, and generated a revenue of approximately KRW 26 billion (ca. EUR 17 million) in 2023 with 8 employees.

“This acquisition will be an important step in expanding our footprint in our beauty and personal care market and further enriches our life science portfolio,” remarked Dongjoon Lee, Managing Director of IMCD South Korea. “We are excited to welcome such a dedicated and skilled team to IMCD.

 “I am convinced that YCAM’s extensive resources and knowledge can swiftly integrate into IMCD’s global business model, enhancing its commercial and operational strength in South Korea’s personal care and pharmaceuticals industries,” remarked Munkyum Kim, CEO of YCAM. “My team has been an invaluable asset to the company, and I believe they will have even more opportunities to develop and maximise their potential with IMCD.”
 
The closing of the transaction is subject to customary (regulatory) closing conditions and is expected to take place in the second quarter of 2025.

Attached, the full press release in PDF format, the main visual and photo caption.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.